Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?

[1]  P. van de Borne,et al.  Uric acid and hypertension: a focused review and practical recommendations. , 2019, Journal of hypertension.

[2]  I. Hisatome,et al.  Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy , 2019, European heart journal.

[3]  D. Solomon,et al.  Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study , 2018, Circulation.

[4]  T. Merriman,et al.  Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Kenneth G Saag,et al.  Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout , 2018, The New England journal of medicine.

[6]  S. Bangalore.  Cholesterol variability: a marker for increased risk or a risk factor? , 2017, European heart journal.

[7]  A. Dominiczak,et al.  Serum uric acid and the risk of cardiovascular and renal disease. , 2015, Journal of hypertension.

[8]  F. Messerli,et al.  Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis , 2013, Journal of clinical hypertension.

[9]  叶夏,et al.  Gout , 2011 .

[10]  Rainer Hambrecht,et al.  Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure: Results From 2 Placebo-Controlled Studies , 2002, Circulation.

[11]  M. Burnier,et al.  Renal effects of angiotensin II receptor blockade in normotensive subjects. , 1996, Kidney international.

[12]  F. Messerli,et al.  Serum uric acid in essential hypertension: an indicator of renal vascular involvement. , 1980, Annals of internal medicine.

[13]  J. Laragh,et al.  Hyperuricemia in primary and renal hypertension. , 1966, The New England journal of medicine.

[14]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[15]  J. Wilson.  Gout , 1895, Annals of Internal Medicine.

[16]  K. Leung,et al.  Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.